Skip to main content
Midas Edge

Atrium Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 14, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 14, 2026

RNA$8.38+0.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 6. Exhibits

The following documents are filed as exhibits hereto:

ExhibitNumberDescription
2.1^Separation and Distribution Agreement, dated as of October 25, 2025, among Avidity Biosciences, Inc., Atrium Therapeutics, Inc. and Novartis AG (incorporated by reference to Exhibit 2.1 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on January 30, 2026)
2.2^Agreement and Plan of Merger, dated October 25, 2025, among Avidity Biosciences, Inc., Novartis AG and Ajax Acquisition Sub, Inc. (incorporated by reference to Exhibit 2.2 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on January 30, 2026)
3.1Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on February 17, 2026)
3.2Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on February 17, 2026)
4.1Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on February 17, 2026)
10.1†Transition Services Agreement, dated as of February 26, 2026, by and between Avidity Biosciences, Inc. and Atrium Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 to the Registrant’s Form 8-K (File No. 001-43008) filed with the SEC on February 27, 2026)
10. 2†License Agreement, dated as of October 25, 2025, by and between Avidity Biosciences, Inc. and Atrium Therapeutics, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on January 30, 2026)
10. 3†Amended and Restated License Agreement, dated as of February 26, 2026, by and between Avidity Biosciences, Inc. and Atrium Therapeutics, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant’s Form 8-K (File No. 001-43008) filed with the SEC on February 27, 2026)
10. 4†Research Collaboration and License Agreement, dated as of April 17, 2019, by and between Eli Lilly and Company and Avidity Biosciences, Inc. (incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on January 30, 2026)
10. 5†Research Collaboration and License Agreement, dated as of November 27, 2023, by and between Bristol-Myers Squibb Company and Avidity Biosciences, Inc. (incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on January 30, 2026)
10. 6#Atrium Therapeutics, Inc. 2026 Incentive Award Plan, including forms of grant notices and agreements thereunder (incorporated by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on January 30, 2026)
10. 7#Form of Make Whole Restricted Stock Unit Grant Notice and Make Whole Restricted Stock Unit Agreement under the Atrium Therapeutics, Inc. 2026 Incentive Award Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on February 17, 2026)
10. 8#Atrium Therapeutics, Inc. 2026 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.7 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on January 30, 2026)
10. 9#Atrium Therapeutics, Inc. 2026 Employment Inducement Incentive Award Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 99.1 to the Registrant’s Registration Statement on Form S-8 (File No. 333-295136) filed with the SEC on April 17, 2026)
10. 10#Employment Agreement to be entered into by and between Atrium Therapeutics, Inc. and Kathleen Gallagher (incorporated by reference to Exhibit 10.8 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on February 17, 2026)
10. 11#Employment Agreement to be entered into by and between Atrium Therapeutics, Inc. and Husam Younis (incorporated by reference to Exhibit 10.9 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on February 17, 2026)
10. 12#Employment Agreement to be entered into by and between Atrium Therapeutics, Inc. and Steven Hughes (incorporated by reference to Exhibit 10.10 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on February 17, 2026)
10. 13#Employment Agreement to be entered into by and between Atrium Therapeutics, Inc. and Brendan Winslow (incorporated by reference to Exhibit 10.11 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on February 17, 2026)
10. 14#Employment Agreement to be entered into by and between Atrium Therapeutics, Inc. and Stephanie Kenney (incorporated by reference to Exhibit 10.12 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on February 17, 2026)
10. 15#Employment Agreement to be entered into by and between Atrium Therapeutics, Inc. and Rocio Martin Hoyos (incorporated by reference to Exhibit 10.13 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on February 17, 2026)
10. 16#Atrium Therapeutics, Inc. Non-Employee Director Compensation Program (incorporated by reference to Exhibit 10.14 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on February 17, 2026)
10. 17Form of Indemnification Agreement to be in effect following the Distribution (incorporated by reference to Exhibit 10.15 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on February 17, 2026)
10. 18Amended and Restated Lease Agreement, dated December 18, 2020, by and between ARE-SD Region No. 44, LLC and Avidity Biosciences, Inc. (incorporated by reference to Exhibit 10.16 to the Registrant’s Registration Statement on Form 10-12B/A (File No. 001-43008) filed with the SEC on February 17, 2026)
31.1Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents
104The cover page for the Company's Quarterly Report on Form 10-Q has been formatted in Inline XBRL and contained in Exhibit 101
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.